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 Genetically encoded calcium indicators (GECIs) are Ca
2+
 sensitive fluorescent 
proteins that have expanded the usefulness of optical calcium imaging to longitudinal in 
vivo studies due to their advantage of direct expression in the tissue being imaged. 
Several generations of GECIs have been developed using green fluorescent protein (GFP) 
or one of its variants with each generation improving upon Ca
2+
-binding affinities and 
optical properties. However, the tissue penetration of excitation or emission light through 
tissue is small due to high absorption of available GECI wavelengths, which are shorter 
than the infrared range. The field still lacks a GECI with excitation or emission 
wavelengths in the infrared range, which has significantly less attenuation in biological 
tissue.  Here we propose the development of an infrared GECI by insertion of the Ca
2+
-
binding domain calmodulin (CaM) into regions surrounding the biliverdin chromophore 
binding pocket of infrared fluorescent protein (iRFP). We proposed seven DNA 
constructs of iRFP with different CaM insertion sites. Six of the seven DNA constructs 
were successfully produced with protein expressed from one of these constructs 
exhibiting similar optical properties to iRFP, showing successful receptor insertion into 
iRFP. Though our initial Ca
2+
 sensitivity test to monitor change in fluorescence due to 
Ca
2+
 binding is not conclusive, we open the field of GECI engineering to exciting new 
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Biological Role of Calcium 
 
 The calcium ion (Ca
2+
) performs diverse functions in cell signaling and 
physiology, including cellular differentiation, motility, proliferation, apoptosis, gene 





]i) is responsible for release of neurotransmitter vesicles from 
presynaptic neurons and synaptic plasticity in postsynaptic neurons. In muscle cells, 
transient increases in [Ca
2+
]i underlie the coupling between electrical excitation and 





 release is the means by which calcium transients mediate 
excitation-contraction coupling in cardiomyocytes. Upon depolarization of the 
cardiomyocyte, L-type Ca
2+
 channels localized in the cell membrane along transverse 
tubules pass calcium ions down their electrochemical gradient into the cell. These Ca
2+
 
ions interact with ryanodine receptors (RyR) in the membrane of the sarcoplasmic 
reticulum (SR) which is located near the T-tubules. Upon binding of Ca
2+
, RyRs release 
large amounts of calcium ions from the SR into the cytosol, increasing [Ca
2+
]i 10-fold 
from around 100 nM to more than 1 μM [2]. 
 Calcium ions diffuse to the actin and myosin contractile fibers where they become 
chelated in site II of the regulatory domain of troponin C (TnC). This event alters the 
structure of the regulatory domain, exposing hydrophobic residues that interact with 
2 
troponin I (TnI), disrupting its inhibitory effect on actin-myosin interactions [3]. Once 
allowed to interact, myosin heads walk along actin filaments, consuming ATP and 
shortening sarcomere length which produces contraction in the activated cardiomyocyte. 
Myocyte contraction is a transitory event because free Ca
2+
 ions in the cytosol are 
continually sequestered back into the SR through the sarco/endoplasmic reticulum 
ATPase (SERCA) and removed from the cell through Ca
2+





exchanger (NCX).  
 Alterations of calcium handling in the excitation-contraction process are known to 
occur in cardiac disease [2]. For instance, total Ca
2+
 content of cardiomyocytes is known 
to be decreased in some types of heart failure. With less available Ca
2+
 to interact with 
contractile elements, the total force of contraction is lessened, decreasing the heart’s 
pumping efficiency. Overloading of Ca
2+
 in the SR along with increased sensitivity in 
RyR can cause spontaneous Ca
2+
 leaks into the cytosol [2]. This spontaneous increase in 
[Ca
2+
]i during diastole is countered by increased activity in NCX. Because three Na
+
 ions 
are brought into the cell for each Ca
2+
 ion exiting, there is a net inward current that causes 
early (EAD) or delayed (DAD) afterdepolarization. This depolarization can lead to 
extrasystoles that may be arrhythmogenic. 
Monitoring changes in calcium handling during disease development and 
treatment in cells and tissue preparations has been of great importance for understanding 
cellular mechanisms. In monitoring the spatial distribution of Ca
2+
 ions within whole 
tissues and subcellular compartments, optical calcium imaging has been an indispensable 
technique. This imaging technique makes use of a diverse range of calcium probes (Ca
2+
-
chelating structures coupled with fluorescent moieties) in order to report changes in Ca
2+
 
concentration as changes in fluorescence intensity. 
3 
Calcium Imaging 
Fluorescence is the process by which a molecule absorbs and emits photon 
energy. It occurs after photon energy is absorbed by and thereby excites a ground state 
electron in the molecule, moving it into a higher energy state [4]. After dissipation of 
some vibrational energy, the electron will return to the ground state, emitting the 
remaining absorbed energy in the form of a photon with less energy and longer 
wavelength than the absorbed photon. The fluorescence phenomenon occurs seemingly 
instantaneously following excitation. The difference between excitation and emission 
wavelengths of a fluorescent molecule is known as the Stoke’s shift. Imaging fluorescent 
molecules at their emission wavelength during excitation allows localization of the 
fluorescent molecule. When a fluorescent molecule preferentially localizes to a particular 
region or colocalizes with another molecule, it is considered a probe, because it allows 
spatial visualization of a particular space or target molecule. Calcium probes display 
quenching or alteration of fluorescence when Ca
2+
 is not bound which decreases 
background signal where there is no Ca
2+
 for the probe to bind.  
 Two classes of fluorescent calcium probes currently exist [5]. The first class 
consists of calcium dyes, which are small synthetic molecules that change fluorescence 
upon chelating Ca
2+
 ion. The second class is genetically encoded calcium indicators 
(GECIs), which are fluorescent proteins that are Ca
2+
 sensitive due to fusion of a 
fluorescent protein with a Ca
2+
-binding peptide. There are strengths and limitations 
associated with both of these classes of probes that should be taken into account before 





 Commonly used calcium dyes include fura-2, rhod-2 and fluo-4. These dyes 
utilize stilbene, rhodamine and fluorescein as their respective fluorescent moieties, each 
of which is coupled with the BAPTA Ca
2+
 chelating moiety. The BAPTA moiety 
contains high electron density which is able to be donated into the highly conjugated 
fluorescent moieties. When Ca
2+
 becomes chelated by the oxygen atoms in BAPTA, 
electron density donation is decreased, increasing fluorescence intensity or shifting 
excitation or emission wavelength peaks of the molecule [6]. Because of the large 
negative charge on the BAPTA moiety, the carboxylate ions are derivitized as 
acetoxymethyl esters (AM) to give the molecule a neutral charge, allowing it to diffuse 
across cell membranes. These AM derivatives are then cleaved with endogenous 
intracellular esterases, restoring the negative charge and preventing the calcium dye from 
diffusing back out of the cell. 
The on/off kinetics for the BAPTA-derived calcium dyes is typically around 
2/100 ms, a highly desirable property when used to visualize short-lived calcium 
transients [5]. They also have calcium affinities that are beneficial for monitoring 
physiologic changes in [Ca
2+
]i. These binding affinities are generally reported as 
dissociation constants (Kd), which is the concentration of Ca
2+
 at which half of the 
species in solution are bound to Ca
2+
. Calcium dyes generally have Kds ranging from 200 
to 600 nM, with some desirable exceptions. 
 Fura-2 is one of the oldest available calcium dyes and is still used frequently due 
to its ratiometric property [7]. Binding of Ca
2+
 (Kd = 224 nM) shifts the excitation 
wavelength from 380 to 340 nm while keeping emission at 510 nm. This allows a more 
5 
quantitative measure of [Ca
2+
]i as the ratiometric fluorescence imaging method is not 
dependent upon the concentration of calcium dye in the cell. 
 The use of fluo-4 quickly caught on due to its wavelength compatibility (494/516 
nm ex/em) with fluorescein optical filter sets already available at the time [8] and its 120-
fold increase in fluorescence intensity upon binding Ca
2+
 (Kd = 350 nM). Rhod-2 is also 
an intensiometric calcium dye with 552/581 ex/em fluorescence wavelengths and a Kd of 
570 nM. These optical properties are more red-shifted than fura-2 or fluo-4. Another 
benefit to rhod-2 is that it is preferentially taken up into the mitochondrial subcellular 
compartment because it contains a net positive charge as an AM derivative [9]. However, 
its use as a mitochondrial Ca
2+
 reporter is much improved when reduced to dihydro-rhod-
2-AM, which experiences fluorescence quenching until oxidized in the mitochondria to 
rhod-2. This helps to prevent simultaneous reporting of cytosolic [Ca
2+
]. 
 Other methods have been used to increase the ability to localize calcium dyes or 
alter their Ca
2+
 affinities for more specified applications. Boca-1 BG (522/536 ex/em and 
200 nM Kd) has a 180-fold change in fluorescence intensity and has been developed to 
covalently bind to SNAP-tagged proteins, making it able to colocalize into desired 
subcellular spaces [10]. X-Rhod-5F has been engineered with decreased Ca
2+
 binding 
affinity (1.6 μM Kd), making it more useful for imaging in regions with high basal [Ca
2+
] 
such as the endoplasmic reticulum. 
 KFCA is a more recently developed calcium dye that has excitation and emission 
wavelengths in the near infrared range [11]. This contains a BODIPY based fluorescent 
moiety with sharp 650/660 nm ex/em peaks and a Kd of 500 nM. Similar to fluo-4, KFCA 
also experiences 120-fold change in fluorescence intensity upon binding Ca
2+
. The far red 
shifted wavelengths of this calcium dye are of particular interest to deep tissue imaging. 
6 
While calcium dyes are more easily applied in experimental application and can 
be more easily engineered to obtain desired Ca
2+
-binding affinities and fluorescence 
change, they suffer major limitations for longitudinal (repeatable studies over the lifetime 
of a subject) and noninvasive use in vivo. Because calcium dyes are delivered to the 
cytosol via passive diffusion across the cell membrane, the dye loading process requires 
removal of tissue for bathing in a dye-containing solution or invasive perfusion 
procedures if done without tissue removal [12]. This process is also nonselective with 
regard to cell type and undesirable background signal lowers signal to noise ratio during 
imaging. Cell-specific delivery of calcium dyes can also be done by patch pipette, but this 
technique is impractical for multicellular tissue imaging. Dyes also suffer from wash out 
from the cell, decreasing signal intensity over the course of imaging. These limitations 
prohibit noninvasive application of calcium dyes for in vivo calcium imaging. 
 
Genetically Encoded Calcium Indicators 
 GECIs have been largely complementary to calcium dyes’ abilities. Though 
GECIs suffer from smaller changes in fluorescence and more limited Ca
2+
-binding 
affinities, they have the advantage of being expressed in vivo. The gene encoding a GECI 
can be delivered to the nucleus of a cell via transfection [13], viral transduction [14] or 
development of a transgenic organism [15]. Localization of expression can also be highly 
specific when coupled with tissue-specific promoters and/or subcellular localization tags 
[16, 17]. These strengths make GECIs an efficient tool for noninvasive calcium imaging 
in vivo. 
GECI engineering has previously been achieved by either fusion of a single 




peptide [18] or connecting two fluorescent proteins with a Ca
2+
-binding peptide and a 
peptide that can interact with the Ca
2+
-binding peptide [19, 20, 21]. The former method 
produces changes in fluorescence intensity while the latter can make use of Förster 
resonance energy transfer (FRET) to provide a change in the ratio of intensities of two 
emission wavelengths. Examples from each of these types of GECIs include camgaroo 
[18], GCaMP [19] and cameleon [20]. 
Camgaroo was produced by replacing the 145
th
 amino acid of a GFP-like protein 
with the Ca
2+
-binding peptide calmodulin (CaM) [18]. Ca
2+
 and pH titrations revealed 
that the binding of Ca
2+
 to the fused CaM domain alters its structure in a similar manner 
to TnC (a close relative of CaM) which causes deprotonation of the chromophore, 
changing the ratio of 400 nm to 490 nm emission. GCaMP also utilizes fusion of CaM to 
GFP, however, the GFP is circularly permuted (cp) and CaM is placed at the end of 
cpGFP while the CaM-binding peptide of myosin light chain kinase (M13) is placed at 
the beginning of cpGFP [19]. The fluorescence intensity change in GCaMP is due to M13 
interacting with CaM after CaM binds Ca
2+
, thereby restoring natural GFP chromophore 
structure by bringing the two ends of cpGFP closer together [22]. 
The FRET-based cameleon is produced by using CaM and M13 to link two 
different GFP-like proteins (such as YFP and CFP) together [20]. Upon binding of Ca
2+
 
to CaM, M13 folds in to interact with CaM, bringing YFP closer to CFP. When CFP is 
excited at 440 nm, it undergoes nonradiative FRET with YFP causing the YFP 
chromophore to emit 535 nm wavelength light. In the absence of Ca
2+
, fluorescence 
emission from only the CFP is detected at 480 nm. Variants on cameleon have also been 
produced using TnC instead of CaM as the Ca
2+
-binding domain and TnI instead of M13 
8 
as the interaction peptide in an effort to prevent interaction of the fused CaM domain 
with targets of its multiple cellular signaling pathways [21]. 
 
GECI Calcium Binding Affinities 
CaM and TnC are effective fusion inserts for conferring Ca
2+
 sensitivity to 
fluorescent proteins due to their Ca
2+
-chelating structure. Both belong to a dumb-bell 
shaped protein family containing two domains (N and C) linked by a flexible strand of 
amino acids. Each domain contains two Ca
2+
-chelating sites (I and II on the N domain 
and III and IV on the C domain) in the form of EF hand motifs that are two helices (E and 
F) connected by a loop containing multiple negatively charged residues involved in Ca
2+
 
chelation. The helices comprising the EF hands change conformation with respect to one 
another when Ca
2+
 binds to the loop between them, exposing previously buried 
hydrophobic residues. These activated regions can then bind to a number of different 
targets within the cell including TnI and actin for the N and C domains of TnC, 
respectively [3], and a host of different targets for CaM [23]. When ligated into particular 
regions around the chromophore of fluorescent proteins, these domains will bind Ca
2+
 
ions and change conformation, affecting the fluorescence intensity of the fluorescent 
protein with which they are fused.  
 The Ca
2+
-binding affinities of the CaM and TnC inserts are important to consider 
when designing a GECI. The N and C terminal domains of CaM and TnC consist of 
Ca
2+
-binding sites I/II and III/IV, respectively. CaM N and C terminal Kd have been 
measured at 2.4 μM and 18 μM [24]. The N terminal domain of skeletal troponin C 
(sTnC) has a much lower affinity for Ca
2+
 (Kd = 32 μM) compared to the C terminal 
domain (Kd = 200 nM) [25, 26]. Cardiac troponin C (cTnC) differs from sTnC in that site 
9 
I is nonfunctional and site II has about 10-fold more affinity (Kd = 3.8 μM) compared to 
the N terminal of sTnC [27]. Presence of M13 with CaM increases its Ca
2+
 affinity nearly 
100-fold to a Kd of 26 nM [24]; and interestingly, when M13 is fused to the C terminal of 
CaM with a GG linker, there is a biphasic response with Kds of 80 nM and 2 μM with an 
overall Kd of around 500 nM. 
 These Ca
2+
 affinities affect the GECIs in which they are incorporated but a 
GECI’s Kd is not necessarily the same as the insert it contains. For instance, camgaroo, 
which contains the CaM insert, has a Kd of 7 μM which is similar to the overall biphasic 
response of CaM N and C terminal Ca
2+
 binding [18]. But, the CaM and M13 containing 
GECI GCaMP has a Kd of 235 nM compared to the 26 nM Kd of the CaM and M13 
peptides alone [19]. The cameleon derivatives with CaM and M13 fusion may have 
similar or much lower affinities compared to the CaMM13 hybrid molecule [14]. The 
receptor insert used in our study was CaM. 
 
Advantages of Infrared Imaging 
With all of the successful GECIs heretofore engineered, GECIs’ full potential as 
noninvasive in vivo calcium probes has not yet been realized. This is because GECIs are 
not yet available in the infrared range (700 to 1,000 nm) for excitation or emission 
wavelengths. The infrared wavelength range exhibits both decreased attenuation and 
detectable autofluorescence in biological tissue [28]. Thus, although GECIs are expressed 
in vivo, imaging still requires removal or exposure of the tissue being imaged for either 
penetration of excitation wavelength light to the tissue or visualization of the emission 
wavelength signal produced in the tissue.  
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Another incentive to move imaging into the infrared range is the recent 
development of an exciting new optical imaging technique known as fluorescence 
molecular tomography (FMT) that is able to calculate a pseudo 3D distribution of 
fluorophores in biological tissue [29]. A point source of light is applied below the scan 
subject at many locations and an image of the light transmitted through the subject is 
acquired from above for each location of the point source applied below. This process is 
performed with the point source set to the emission wavelength of the fluorophore, where 
there is no fluorescence detected, and the camera filtered to only receive light at the 
emission wavelength. This allows mapping of the diffusion and attenuation of light 
through the tissue being imaged. The same scan is then performed with the point source 
set to the excitation wavelength of the fluorophore and the camera still detecting emission 
wavelength light. In this manner, the only signal detected by the camera is originating 
from the locations of the fluorophores. These scan data are fed into complex algorithms 
describing the propagation of light through tissue, creating an inverse problem that can be 
solved by regularization and a number of techniques including singular value 




The purpose of the current study is to propose that an infrared fluorescent protein 
could be used with the previously outlined GECI engineering techniques to produce a 
Ca
2+
 sensitive infrared fluorescent protein (an infrared GECI). This novel calcium probe 
will enable calcium imaging of deeper tissues, allowing noninvasive calcium imaging in 
11 
vivo. We seek to accomplish development of this novel tool by inserting CaM into a 
recently developed infrared fluorescent protein known as iRFP. 
 The infrared fluorescent protein we chose for testing was one recently developed 
by Filonov et. al. and termed iRFP [30]. iRFP is derived from a Rhodopseudomonas 
palustris bacteriophytochrome (RpBphP2) and has more than twice the signal to 
background ratio in vivo compared to far red GFP variants and around 18-fold higher 
brightness compared to the previously used infrared protein IFP1.4. iRFP covalently 
binds the tetrapyrrole biliverdin to form its chromophore, giving the protein a green color 
due to the  high absorbance in the 350 to 450 nm wavelength range by biliverdin’s 
conjugated pi system and producing fluorescence emission at 715 nm when excited with 
690 nm light. We propose that introducing Ca
2+
 sensitivity into iRFP’s infrared excitation 
and emission wavelengths would produce an infrared GECI that would allow in vivo 
calcium imaging at depths not currently attainable. When such a tool is used with FMT, 
pseudo 3D calcium imaging may be achievable where only 2D surface mapping has 















 The primary structures of RpBphP3 (a close relative of RpBphP2), RpBphP2, 
iRFP, and CaM in addition to the available crystalline structure of RpBphP3 [31] and 
CaM [32] were viewed in PyMOL as templates for construct design. We first identified 
residues in the RpBphP3 crystalline structure that were involved with biliverdin 
chromophore binding [31]. Then we identified pi conjugated His, Phe, Tyr, and Trp 
residues facing toward the chromophore that might be involved in establishing the 
fluorescence properties of iRFP. Sites in the immediate vicinity of the chromophore were 
then identified that, after removal of a number of amino acid residues, could spatially 
accommodate insertion of the CaM protein crystalline structure (residues A2-A148) as 
determined by loading both structures into the same PyMOL session and placing them in 
a conformation that may be adopted in the final GECI structure. 
We wanted the protein domains of the designed constructs to fold in such a way 
that they adopted similar structures to those resolved separately for iRFP and CaM. If 
they folded in this manner, the biliverdin chromophore binding pocket could be 
maintained in the new protein constructs while allowing slight changes in CaM 
conformation due to Ca
2+
 binding to cause minor changes in the locations of the 
identified pi conjugated residues with respect to the chromophore. Seven ligation sites 
were chosen that met these criteria (Figure 1) where we would replace one or more 
13 
residues of iRFP with the CaM insert and linker peptides (GAP linker on N terminal of 
CaM and VD linker on C terminal of CaM). With insertion of CaM in these regions, 
Ca
2+
-induced conformational changes of the CaM insert might affect a change in iRFP 
chromophore structure thereby making its fluorescence properties Ca
2+
 sensitive. 
Considerable flexibility was assumed in the linker peptides and strand connecting 
the N and C domains of CaM such that the distance between the N and C terminals of the 
CaM insert could span the length of residues removed at each site. As such, residues 211-
216 were removed for ligation at site 1. Likewise, residues 231-232, 236, 270-276, 288-
289, 301-302, and 324-329 were removed for ligation into sites 2, 3, 4, 5, 6 and 7. We 
recognize the highly speculative nature of this method of construct design. More robust 
methods may have been used such as molecular modeling. However, there is no resolved 
 
 
Figure 1 – Calmodulin ligation sites in iRFP for construct development. Crystalline 
structure of RpBphP3, a close relative to iRFP, shown with biliverdin chromophore 
(green) [31]. Seven ligation sites are in magenta, numbered from 1 to 7. These residues 
were replaced by CaM with the GAP and VD linker peptides. Residues colored in yellow 





structure available for iRFP which would be ideal for molecular modeling. Also, due to 
the many advances in molecular cloning techniques, computational studies would take 
considerably more time to perform than generating a number of different constructs 
through molecular biology cloning techniques. 
Thus, seven DNA constructs (designated C1-C7) were designed which were 
sequentially composed of the portion of the iRFP gene upstream of a ligation site, the 
CaM gene insert and the portion of the iRFP gene downstream of a ligation site (Figure 
2). For each of the seven constructs, the portion of the iRFP gene upstream of the ligation 
site was termed fragment A and the downstream portion was termed fragment C. These 





Figure 2 – Primary structures of final constructs. Constructs consist of fragments A, B 
and C joined by restriction sites AscI and SalI and framed by NcoI and HindIII restriction 
sites. Green fragments (A and B) are the indicated residues of wild type iRFP (WT iRFP) 





The common CaM insert was termed fragment B for each construct. Altogether, 
fragments A, B (450 bp) and C make open reading frames (ORF) which translate to 
proteins around 500 amino acid (AA) residues for the novel constructs. The final protein 
constructs are around 55 kDa in size. 
 
Construct Fragment Production 
The pBAD/His-B-iRFP and pDONR223-CALM3 plasmids deposited by 
Vladislav Verkhusha [30] and William Hahn [33], respectively, were obtained from 
Addgene. Polymerase chain reaction (PCR) was used to amplify the A, B and C 
fragments that would compose the DNA constructs similar to the method performed for 
the production of camgaroo (Figure 3) [18]. The common B fragment was amplified 
using oligonucleotide primers designed to have 3’ ends complementary to the ends of the 
CALM3 insert in the pDONR223-CALM3 plasmid with 5’ ends containing the 





Figure 3 – Primer setup for PCR method of acquiring fragments A, B and C. Green 
double stranded DNA is iRFP. Blue double stranded DNA is CaM. Ligation site is shown 
as red dashed line. Restriction site sequences for AscI and SalI were contained within the 





site on the antisense primer. For fragment A amplification, a common sense primer 
matching the 5’ end of the iRFP sense strand was used with one of seven unique 
antisense primers with 3’ ends designed to match the iRFP antisense strand just upstream 
of their respective ligation sites and 5’ ends that contain nucleotides coding the AscI 
restriction site. Likewise, for fragment C amplification, a common antisense primer 
matching the 5’ end of the iRFP antisense strand was used with one of seven unique 
sense primers with 3’ ends designed to match the iRFP sense strand just downstream of 
their respective ligation sites and 5’ ends that contain nucleotides coding the SalI 
restriction site. The iRFP gene already contained an N terminal His tag and was flanked 
by restriction sites NcoI and HindIII which were incorporated into the common sense and 
antisense primers. Because PCR primer cooperation is essential to fragment 
amplification, all primer pairs needed to have similar melting temperatures (Tm). The 
amount of GC content in unique primers for sites 3, 4, 5 and 7 required use with longer 
versions of the common sense or antisense primers. Variations of antisense primers for 
5A and 7A were also produced due to difficult PCR reactions. These primers contained 
complementary regions before and after the AscI-coding nucleotides. All primers ensured 
that the final constructs would be in frame after ligations were completed.  
PCR was performed with Platinum Taq DNA Polymerase from Invitrogen 
according to the recommended protocol with 2 mM MgCl2. Fresh PCR product was ran 
on a 0.7% agarose gel stained with ethidium bromide (EtBr) to confirm presence of 
fragment with the desired length and visualize fragments of incorrect lengths that resulted 
from nonspecific primer binding. For reactions that resulted in no visible bands on 
agarose gel, the concentration of MgCl2 was increased to 3 mM to promote primer 
binding at the expense of nonspecific binding. 
17 
The fresh PCR product fragments generated by Taq polymerase contained single 
3’ adenine overhangs on each strand when amplified in the absence of a proofreading 
polymerase. These fragments could then be TOPO-cloned using a TOPO TA cloning kit 
from Invitrogen into linear pCR2.1-TOPO vector, which contains 3’ thymine overhangs 
in the cloning ORF, using topoisomerase enzyme. TOPO cloning creates a PCR 
fragment-containing circular plasmid that can be replicated when transformed into DH5α 
bacterial cells and plated on LB plates containing 50 μg/mL kanamycin and 40 μL of 
both 40 mg/mL X-Gal and 100 mM IPTG. Because the fragment cloning site in pCR2.1-
TOPO is contained in a LacZα ORF which codes for the beta-galactosidase enzyme, 
insertion of a fragment disrupts production of this enzyme which normally converts X-
Gal into blue products when expressed with IPTG. Therefore, bacterial colonies 
containing fragment insertions are white compared to the blue colonies containing 
pCR2.1-TOPO vector with no PCR fragment insertion. 
White colonies were selected and grown in 10 mL LB overnight cultures to 
amplify fragment-containing plasmids. Plasmids were isolated with a QIAGEN Plasmid 
Mini kit and digested in New England Biolabs (NEB) recommended restriction enzyme 
buffers with restriction enzymes corresponding to the fragment’s unique restriction site 
and another compatible site in the pCR2.1-TOPO vector (NcoI and AscI for fragment A, 
NcoI and SalI for fragment B, EcoRI and HindIII for fragment C) and run on 0.7% 
agarose gels to ensure correct fragment sizes and determine fragment orientation in the 
cloning site. For plasmids containing the correct fragment size, M13 forward and reverse 
primers were added in separate samples and sent to the DNA sequencing core to ensure 
no deleterious mutations resulted from PCR amplification of the fragments. 
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Fragment Ligation Procedure 
When desired fragments were confirmed by sequencing, they were sequentially 
moved into the pCDFDuet-1 bacterial expression plasmid which contained NcoI, AscI, 
SalI, and HindIII restriction sites in the desired sequence and orientation for building the 
full DNA constructs (Figure 4). Each of the unique A fragments and the pCDF backbone 
were isolated by double digestion with NcoI and AscI enzymes. The backbone and 
fragments were combined in a vector to insert ratio of 1:3 and ligated using T4 DNA 
ligase according to NEB protocol. Meanwhile, each of the unique C fragments and the 





Figure 4 – Ligation method for creating final constructs. Two ligation steps combine 
fragments A, B and C into expression vector pCDFDuet-1. For C7, fragment B was 
added to pCR2.1-TOPO containing fragment C via digestion with SalI and EcoRV. The 






SalI and HindIII enzymes and the C fragments were ligated adjacent to the B fragment. 
The plasmids containing adjacent BC fragments were then double digested with AscI and 
HindIII and ligated into the double digested pCDFDuet-1 vector containing the A 
fragment that corresponded to the C fragment insert. Wild type iRFP (WT iRFP) was also 
cloned from the pBAD/His-B vector into pCDFDuet-1 with NcoI and HindIII sites. 
The only exception to this cloning protocol was for construct 7 which had a C 
fragment less than 100 bp in length. For this construct, fragment B was cloned into the 
pCR2.1 vector containing fragment 7C with cutting and ligating at sites NcoI and SalI. 
Then the BC adjacent fragment was ligated into the pCDFDuet-1 vector containing the 
fragment 7A. For each cloning step, digested plasmids were run on 0.7% agarose gels 
and the desired inserts and backbones were extracted from the gel using a QIAquick Gel 
Extraction kit. After each ligation reaction, the fresh ligation products were transformed 
into DH5α cells and plated overnight. Colonies were selected from the plates for 10 mL 
overnight cultures and plasmid isolation the next morning. Digestions were performed on 
the purified plasmids to determine which colonies contained the successful ligation 
product. 
 
Protein Purification and Optical Characterization 
Due to difficulties with obtaining A and C fragments for construct 4, only the full 
DNA constructs (C1, C2, C3, C5, C6 and C7) and the WT iRFP gene were transformed 
into BL21 PLysS competent cells along with the pAT-BV vector obtained from Clark 
Lagarias for coexpression of heme oxygenase (HO1), which provides biosynthesis of 
biliverdin from endogenous heme in E. coli for iRFP chromophore formation [34]. 
Colonies were selected with all of three antibiotics: 50 μg/mL spectinomycin (for 
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pCDFDuet-1 vector containing WT iRFP and constructs), 50 μg/mL kanamycin (for 
pAT-BV) and 34 μg/mL chloramphenicol (for the PLysS plasmid in the BL21 competent 
cells). Individual colonies were inoculated into 50 mL cultures in Luria-Bertani (LB) 
broth containing antibiotics and incubated at 37° C overnight. The next morning, the 
overnight cultures were diluted to an optical density (OD) of 0.1 at 600 nm into 1 L of 
LB medium containing 0.1 mM δ-aminolevulinic acid (ALA) and 0.05 mM FeCl3 and 
incubated at 30° C until reaching 0.6 OD. The addition of ALA and FeCl3 helps to 
facilitate production of heme for subsequent catabolism into biliverdin. At 0.6 OD, 
expression was induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
except for a WT iRFP culture used as the noninduced control. Expression was continued 
at 30° C for 4 hours. Cells were then incubated on ice for 5 min, spun at 3,000 RPM for 
20 min at 4° C, resuspended in 20 mL of 20 mM Tris pH 7.5 and spun again. 
Supernatants were discarded and cell pellets were frozen. 
All frozen pellets were resuspended in 30 mLs lysis buffer (50 mM monobasic 
sodium phosphate (NaH2PO4) and 300 mM sodium chloride (NaCl)) and sonicated for 5 
min on ice with 10 s cycle length and 50% duty cycle. Lysates were spun at 15,000 RCF 
for 45 min at 4° C. The supernatant was incubated with 250 μL of 50% HisLink Ni-NTA 
bead slurry from Promega overnight at 4° C in a rotorack to preferentially bind the His-
tagged constructs and WT iRFP for purification. Ni-NTA beads were washed and eluted 
sequentially with 50 mM, 250 mM and 500 mM imidazole the next morning to obtain 
purified constructs and WT iRFP. The purified constructs and WT iRFP were then 
dialyzed into MOPS buffer with 15 kDa cutoff dialysis tubing to remove imidazole and 
stored at 4° C. 
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 Absorbance spectra from 250 to 800 nm were obtained for the constructs and WT 
iRFP using a spectrophotometer. Excitation and emission spectra were also obtained from 
550 to 800 nm with excitation at 700 nm and emission at 715 nm; 400 μL aliquots of the 
purified protein were spiked with either 40 mM EDTA to chelate any free Ca
2+
 or 20 mM 
CaCl2. Absorbance and fluorescence spectra were also obtained for these aliquots to find 
any changes between the non-Ca
2+














 PCR yielded all required fragments for building constructs 1, 2, 3, 5, 6 and 7. 
Fragment sequencing revealed a silent mutation in fragment 1A at 260 bp and a removal 
of three nucleotides from 3A such that it contained only five His residues instead of six in 
the His tag, keeping the length of the fragment in frame. Multiple PCR attempts at 
fragment B amplification resulted in deleterious mutations. Two clones of fragment B 
containing mutations on opposite sides of a ClaI restriction site were cut with ClaI and 
XbaI to isolate the nonmutated regions of each clone. These regions were then ligated 
together to obtain a nonmutated version of fragment B, confirmed by sequencing.  
None of the initial attempts at PCR amplification for fragments 4A or 4C were 
successful. After increasing the concentration of MgCl2 to 3 mM to promote primer 
binding, some products of the right size were obtained but were also fraught with 
mutations. Construct 4 was therefore abandoned with attention turned to the other 
successfully generated construct fragments. 5A and 7A were able to be obtained using the 
newly designed primers and QIAGEN Multiplex PCR kit.  
 Initial attempts at ligation consisted of combining all digested fragments A, B and 
C with the cut pCDF backbone. However, ligation efficiency was too low to generate 
colonies after transformation due to the low probability of all four ligation sites coming 
together in the same reaction. Thus, the stepwise ligation procedure was preferred, 
though it was considerably more tedious and time-consuming. Ligations eventually 
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successfully generated each of the six remaining full constructs, confirmed by restriction 
enzyme double digestion with NcoI/AscI (for fragment A) and NcoI/HindIII (for full 
length) (Figure 5). Sequencing results with PACYCDuetUP1 and DuetDOWN-1 primers 
for the entire constructs also confirmed proper fragment arrangement. 
Previous attempts at expression using 10 L fermenter auto-induction resulted in 
production of WT iRFP but not any of the novel constructs. We learned this by 
submitting the FPLC purified protein SDS PAGE gel band thought to be the novel 
constructs for mass spec. The mass spec results came back positive for E. coli lac 
repressor. The fermenter method may yet prove successful with culturing at 30° C and 
possibly require addition of IPTG. However, we turned to smaller-scale 1 L IPTG 
inductions with culturing in shaker flasks. IPTG-induced expression resulted in 
production of correct sized WT iRFP (~38 kDa) and remaining constructs (~55 kDa), 




Figure 5 – Digestion confirming proper fragment construction. Lanes include DNA 
digestion of wild type iRFP (WT) and final constructs (C1-C7, excluding C4). Lower 
bands on left gel are fragment As. Lower bands on right gel are entire gene lengths. The 






C2 and C3 showed significantly less expression than the other constructs, possibly due to 
less protein stability. During Ni-NTA purification, WT iRFP and C1 were a noticeably 
green color when bound to the beads and following elution. The noninduced control 
displayed no color and had no His-tagged proteins in the total lysate.  
 It is interesting to note that all of the bacteria cultures used for construct 
expression also co-expressed HO for biliverdin production. However, only expression of 
HO and WT iRFP or C1 together resulted in bacteria cells with green hue (Figure 7). 
Expression of HO alone resulted in normal colored cells. While we know that our 
expression method does result in degradation of endogenous heme for biliverdin 
production, it appears that expression of HO was not continued long enough to produce 
excessive amounts of biliverdin. 
 The absorbance spectrum for WT iRFP showed peaks at 280, 390 and 695 nm 
with a shoulder at 638 nm on the left side of the 695 nm peak as has been previously 
 
 
Figure 6 – Expression results for WT iRFP and constructs. Coomassie stained gel 
(top) and α-His stained western blot (bottom) of total lysates from noninduced culture 





reported [30]. When compared to the absorbance spectrum of free biliverdin with nearly 
the same peak height at 390 nm, obvious chromophore formation is visible in the WT 
iRFP sample compared to the very low peak in free biliverdin at 695 nm (Figure 8). 
Excitation and emission spectra for WT iRFP had peaks at 695 and 713 nm, 
respectively. Our excitation and emission spectra show large peaks with 20 nm base 
widths appearing at 2 nm lower than the excitation wavelength in the emission spectra 
and at 2 nm higher than the emission wavelength monitored in the excitation spectra. 
These peaks suggest that the detector is picking up excitation wavelength light from the 
light source. These peaks may be eliminated by adjusting time delay between the source 
flash and photomultiplier integration of the emission signal or by narrowing slit width. 
Batch purification of C1 successfully yielded elution fractions containing the 
construct (Figure 9). The absorbance spectrum for construct 1 had similar absorbance 
peaks to WT iRFP with the exception of a 5 nm peak shift and decrease in height from 
the WT iRFP 695 nm peak, placing C1’s peak at 700 nm (Figure 10). Excitation and  
 
 
Figure 7 – Pelleted cultures showing green hue for WT iRFP and C1. The green color of 
WT iRFP and C1 are due to chromophore formation with biliverdin. Color of noninduced 









Figure 8 – Absorbance spectra for iRFP and free biliverdin. Incorporation of biliverdin 
into the chromophore binding pocket of iRFP results in an increase in the 695 nm peak 









Figure 9 – Ni-NTA batch purification of C1. Arrow shows the eluted C1 protein at the 
expected 55 kDa molecular weight. std = standard, TL = total lysate, pel = pellet, sup 
= supernatant, e1 = elution in 50 mM imidazole, e2 = elution in 250 mM imidazole, e3 
= elution in 500 mM imidazole, bead = Ni-NTA beads after elutions, + = positive 






emission spectra for construct 1 were also similar to WT iRFP, though seemingly lower 
in amplitude. However, these traces were not normalized to total chromophore 
concentration as represented by the 390 nm absorbance peak so this difference in peak 
height could simply be due to lower amount of present chromophore. 
Addition of 40 mM EDTA to aliquots of the purified WT iRFP and C1 or addition 
of 20 mM CaCl2 had no effect on the absorbance spectra except for a high rise in 
absorbance at less than 280 nm for the EDTA samples. This had no interference with the 
biliverdin absorbance peak or the chromophore absorbance peak. Emission spectra were 
acquired for C1 without and with calcium saturation (Figure 11). No observable 
difference was seen between the EDTA and CaCl2 conditions. However, due to the 
limited amount of purified protein, no duplicate or triplicate measurements could be 
taken for a statistical analysis. Therefore, these studies must be repeated upon purification 
of additional protein. 
 
Figure 10 – Absorbance spectra for WT iRFP and C1. Note the wavelength shift from 
695 nm for WT iRFP to 700 nm for C1 along with a decrease in maximum absorbance 








Figure 11 – Emission spectra for C1 in the absence and presence of calcium ions. 
Results are inconclusive for calcium sensitivity test on C1 emission. The large peak in 
each trace is thought to be artifact from the light source. Statistical analysis is not 















 Our results for expression of construct 1 show that receptor insertion into iRFP 
can be accomplished with successful binding of the biliverdin chromophore. This success 
holds exciting new possibilities for GECI engineering which has been limited to GFP 
variants up to this point. Though more conclusive studies with C1 fluorescence changes 
in the absence or saturation of Ca
2+
 may prove C1 to be Ca
2+
 insensitive, we have 
demonstrated the possibility that a different insert could lead to a successful infrared 
GECI. 
 Experimental determination of fluorescence sensitivity of calcium probes to Ca
2+
 
is typically performed by measuring emission wavelength fluorescence intensity in 
aliquots of the purified protein containing various concentrations of Ca
2+





 M. If construct 1 is a feasible GECI, we should see a sigmoidal 




 to a maximum 




. Because we selected CaM as the insert, similar to 
camgaroo, we would also expect the sigmoidal curve to cross the 50% maximal 
fluorescence intensity level somewhere around 10
-6
 M. Excitation and emission spectra 
may also be obtained for each sample to check for any changes in peak wavelengths. If 






 While our primary focus is in demonstrating successful receptor insertion into 
iRFP, CaM, with an overall Kd of around 10 μM, is a less than ideal insert for visualizing 
[Ca
2+
]i fluctuations in cardiomyocyte or neuron cytosol which range from 100 nm to 1.3 
μM [2]. With such a low Ca2+ affinity, very few of the infrared GECI containing the CaM 
insert would bind Ca
2+
 at peak [Ca
2+
]i, though CaM inserts resulting in affinities of 
greater than 2 μM have proven effective for monitoring [Ca2+] in the ER or mitochondria. 
The GECI engineering techniques that have resulted in Kd values ideal for cardiomyocyte 
cytosolic calcium transient imaging require the additional use of M13 in a circular 
permutation of the fluorescent protein or in conjunction with a second fluorescent protein 
with excitation wavelength near the emission wavelength of the first fluorescent protein 
to produce FRET between the two. The latter method may be accomplished with use of 
eqFP670, a red-shifted variant of katushka, a protein isolated from the E. quadricolor sea 
anemone [35]. eqFP670 exhibits emission at 670 nm which can excite iRFP, but may 
only result in half the excitation energy required for maximum emission intensity from 
iRFP. This scenario is likely more feasible than the circular permutation approach using 
CaM and M13 due to iRFP’s different structure as compared to GFP. 
 Compared to GFP’s structure of a ß barrel surrounding a residue-derived 
chromophore, iRFP is composed of a knot-like structure with two domains [31]. The PAS 
domain is the N terminal of iRFP and contains the Cys residue that covalently binds to 
biliverdin. The C terminal is contained by the GAF domain which comprises the 
chromophore binding pocket. The N terminal of the PAS domain is surrounded by a large 
loop of the GAF domain, forming the knot. Though GFP is known to self-assemble into 
its properly folded structure, iRFP is not known to behave this way, making successful 
receptor insertion of a 150 residue domain even more significant. However, iRFP’s knot-
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like structure and the large distance between the N and C terminals make circular 
permutation unlikely. 
 Other inserts have provided GECIs with higher Ca
2+
 binding affinity such as TN-
humcTnC, which contains only sites I-III of TnC’s EF hand motifs as the insert between 
cyan fluorescent protein (CFP) and citrine [21]. TN-humcTnC has a Kd of only 470 nM, 
which is similar to the affinity of the widely used rhod-2 calcium dye. This affinity is 
comparable to the C terminal domain of TnC. Similar inserts may be tried comprising 
other EF hand motifs from either CaM or TnC. 
The crystal structure of C1 would be of benefit for analyzing possible mutations 
or insert modifications that would have greater possibility of affecting chromophore 
structure by conformational change of the insert upon chelation of Ca
2+
. Molecular 
modeling may also be utilized once a solved structure is available for iRFP and C1, 
though such computational modeling of whole protein structural behavior is lengthy and 
computationally intensive. Once a successful insert is found with or without molecular 
modeling, the infrared GECI can also be subjected to site-directed mutations with high 
throughput FACS sorting to determine mutants with the most practical Ca
2+
-binding 
affinities and fluorescence properties for use in the desired imaging application. 
 The applications for an infrared GECI will be diverse from improving current 
GECI studies by providing increased signal to noise ratio to novel noninvasive 
applications with possible pseudo-3D calcium mapping. Due to the noninvasive nature of 
an infrared GECI, longitudinal studies may also be performed on the same animal over 
the course of disease development or treatment with inducible infrared GECI expression 
at different stages of the disease or treatment [36]. Our understanding of changes in 
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